arrow
A

Andri Rauch

University of Bern
H指数:57
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treat all, treat fast: time from HIV diagnosis to treatment initiation in Switzerland, 1996-2025

对所有患者进行治疗,快速治疗:瑞士1996-2025年从HIV诊断到治疗开始的时间

2026-10-080
OA
Cardiovascular Disease Risk with Integrase Inhibitor-based Antiretroviral Therapy: A Causal Inference Analysis in RESPOND

整合酶抑制剂为基础的抗逆转录病毒疗法的心血管疾病风险:一项在RESPOND中的因果推断分析

2026-08-060
OAAI
Acceptance and preferences for different nicotine substitute products to reduce tobacco smoking in people living with HIV: Results from an internal pilot study of a randomized trial

HIV感染者对减少烟草吸烟的不同尼古丁替代产品的接受度和偏好:一项随机试验内部试点研究的结果

2026-05-010
PRE
Offer of a menu of different nicotine substitute products to REduce Tobacco Use iN pEople living with HIV (RETUNE): a protocol for a pragmatic randomized trial within the Swiss HIV Cohort Study

向HIV感染者提供不同尼古丁替代产品以减少烟草使用(RETUNE):一项在瑞士HIV队列研究中的实用性随机试验方案

2026-04-080
PRE
Do people with HIV really have the choice between oral and injectable ART? Evidence from a multicentric survey in the Swiss HIV cohort study

HIV感染者真的有口服和注射型ART的选择吗?——来自瑞士HIV队列研究多中心调查的证据

2026-04-080
OA
Similar Changes in Proviral Landscapes Over 10 Years in 40 Individuals With Diverging HIV Reservoir Dynamics and Viral Load Kinetics

40例个体中HIV储库动态和病毒载量动力学存在差异的10年间病毒基因组景观的相似变化

2026-04-010
PRE
Risk of Hepatocellular Carcinoma After Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection in People With Human Immunodeficiency Virus

人类免疫缺陷病毒感染者接受直接抗病毒药物治疗丙型肝炎病毒感染后的肝细胞癌风险

2025-12-010
OAAI
Circulating HBV RNA and hepatitis B core-related antigen as determinants of HBsAg loss in persons with HIV in Europe

循环HBV RNA和乙型肝炎核心相关抗原作为欧洲HIV感染者中HBsAg消失的判定指标

2025-11-070
OAAI
Implementing a randomization consent to enable Trials within Cohorts (TwiCs) in the Swiss HIV Cohort Study – A mixed-methods study

在瑞士艾滋病队列研究(Swiss HIV Cohort Study)中实施随机化知情同意以实现队列内试验(TwiCs)——一项混合方法研究

2025-09-120
PREAI
Frequent hepatitis B surface antigen (HBsAg) clearance during tenofovir therapy in persons with HIV/hepatitis B virus coinfection

在HIV/乙型肝炎病毒共感染患者中,替诺福韦治疗期间频繁发生乙型肝炎表面抗原(HBsAg)清除。

2025-02-250
PRE
Unsuccessful Direct Acting Antiviral Hepatitis C Treatment Among People With HIV: Findings From an International Cohort
2024-12-100
OAAI
Integrase Strand Transfer Inhibitor-Related Changes in Body Mass Index and Risk of Diabetes: A Prospective Study From the RESPOND Cohort Consortium
2024-08-095
PRE
Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study

免疫功能受损人群对二价加强SARS-CoV-2疫苗的抗体和T细胞反应: COVERALL-3研究

2024-06-070
OAAI
Self-reported neurocognitive complaints in the Swiss HIV Cohort Study: a viral genome-wide association study
2024-05-310
OAAI
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts
2024-05-019
OAAI
Circulating HBV RNA and Hepatitis B Core-Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy

替诺福韦治疗期间HIV/HBV合并感染和乙型肝炎表面抗原丢失的人的循环HBV RNA和乙型肝炎核心相关抗原轨迹

2024-04-160
OAAI
Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV
2024-03-222
OAAI